東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Resistance to targeted therapies in ...

Prosperi, Jenifer R.

Linked to FindBook

Google Book

Amazon

博客來

Resistance to targeted therapies in breast cancer

Record Type:	Electronic resources : Monograph/item
Title/Author:	Resistance to targeted therapies in breast cancer/ edited by Jenifer R. Prosperi.
other author:	Prosperi, Jenifer R.
Published:	Cham :Springer International Publishing : : 2017.,
Description:	xv, 184 p. :ill., digital ;24 cm.
[NT 15003449]:	Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
Contained By:	Springer eBooks
Subject:	Breast - Cancer -
Online resource:	http://dx.doi.org/10.1007/978-3-319-70142-4
ISBN:	9783319701424

Resistance to targeted therapies in breast cancer
Resistance to targeted therapies in breast cancer[electronic resource] /edited by Jenifer R. Prosperi. - Cham :Springer International Publishing :2017. - xv, 184 p. :ill., digital ;24 cm. - Resistance to targeted anti-cancer therapeutics,v.162196-5501 ;. - Resistance to targeted anti-cancer therapeutics ;v.16..

Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.

We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.

ISBN: 9783319701424

Standard No.: 10.1007/978-3-319-70142-4doiSubjects--Topical Terms:

900056
Breast
--Cancer

LC Class. No.: RC280.B8

Dewey Class. No.: 616.99449061

Resistance to targeted therapies in breast cancer
LDR:02091nmm a2200325 a 4500 001 2112725
003 DE-He213
005 20171204113727.0
006 m d
007 cr nn 008maaau
008 180719s2017 gw s 0 eng d
020 $a 9783319701424 $q (electronic bk.)
020 $a 9783319701417 $q (paper)
024 7 $a 10.1007/978-3-319-70142-4 $2 doi
035 $a 978-3-319-70142-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RC280.B8
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.99449061 $2 23
090 $a RC280.B8 $b R433 2017
245 0 0 $a Resistance to targeted therapies in breast cancer $h [electronic resource] / $c edited by Jenifer R. Prosperi.
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2017.
300 $a xv, 184 p. : $b ill., digital ; $c 24 cm.
490 1 $a Resistance to targeted anti-cancer therapeutics, $x 2196-5501 ; $v v.16
505 0 $a Invasive Breast Cancer Therapy 2017: How Well Are We Hitting The Target? -- Resistance to HER2-targeted therapy -- Endocrine Resistance and Breast Cancer Stem Cells - The Inflammatory Connection That Could Lead to New and Improved Therapy Outcomes -- EGFR Resistance -- Targeting FGFR for the treatment of breast cancer -- Targeted Therapies in Breast Cancer -- Future paradigm of breast cancer resistance and treatment.
520 $a We present an in-depth description of resistance to targeted therapies in breast cancer. Targeted therapies discussed here include those used to treat ER+ or Her2+ breast cancers (i.e., Tamoxifen or trastuzumab) or those targeting signaling pathways aberrantly activated in triple negative breast cancer (i.e., EGFR and Wnt signaling) We have also provided an overview of standard of care as an introduction into the importance of targeted therapy. It is our hope that this volume gives an insight into the landscape of breast cancer treatment, the challenges of targeted therapy, and a glimpse into the future of breast cancer therapy.
650 0 $a Breast $x Cancer $x Chemotherapy. $3 900056
650 0 $a Drug resistance in cancer cells. $3 658434
650 1 4 $a Biomedicine. $3 890831
650 2 4 $a Cancer Research. $3 891172
700 1 $a Prosperi, Jenifer R. $3 3270677
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Resistance to targeted anti-cancer therapeutics ; $v v.16. $3 3270678
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-70142-4
950 $a Biomedical and Life Sciences (Springer-11642)